Physician profile
Paul E Dato
NPI 1588632715
$455,242.89
in general payments reported to CMS, 2019-2025
47 companies · $143K in 2025
The $143K reported for 2025 was more than what 99% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $28K · 2021: $40K · 2022: $52K · 2023: $87K · 2024: $71K · 2025: $143K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $175K · Consulting Fee: $71K · Travel and Lodging: $32K · Food and Beverage: $23K · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $175,169.88 |
| Consulting Fee | $71,020.25 |
| Travel and Lodging | $32,093.45 |
| Food and Beverage | $22,910.77 |
| Education | $105.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $121,772.69 | 2019-2025 | Erleada, Akeega, Rybrevant |
| Bayer Healthcare Pharmaceuticals INC. | $91,636.95 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $68,992.90 | 2019-2025 | Provenge |
| Astellas Pharma US INC | $54,806.66 | 2019-2025 | Xtandi, Padcev |
| Sun Pharmaceutical Industries INC. | $32,942.04 | 2019-2025 | Yonsa |
| Pfizer INC. | $25,592.77 | 2020-2025 | |
| Myovant Sciences INC. | $19,492.13 | 2021-2022 | |
| Edap Technomed INC | $11,390.28 | 2021-2025 | |
| Telix Pharmaceuticals | $9,956.29 | 2023-2025 | Illuccix |
| Novartis Pharmaceuticals Corporation | $4,282.18 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $3,063.42 | 2019-2025 | Adstiladrin |
| Clinical Laserthermia Systems Americas INC. | $1,158.96 | 2022-2023 | Mobile Laser Unit |
| Astrazeneca Pharmaceuticals Lp | $1,133.14 | 2020-2025 | Lynparza |
| Abbvie INC. | $1,086.90 | 2019-2025 | Lupron Depot |
| Myriad Genetic Laboratories, INC. | $1,039.18 | 2020-2025 | Prolaris |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $940.77 | 2023-2025 | Orgovyx |
| Blue Earth Diagnostics | $903.75 | 2019-2025 | Posluma |
| Urogen Pharma, INC. | $887.51 | 2022-2025 | Jelmyto |
| Merck Sharp & Dohme LLC | $785.58 | 2020-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Amgen INC. | $528.46 | 2019-2022 | |
| Progenics Pharmaceuticals, INC. | $356.66 | 2021-2025 | |
| Foundation Medicine, INC. | $296.33 | 2020-2023 | |
| Accord Healthcare, INC. | $273.03 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $249.15 | 2023-2025 | Akeega, Balversa, Erleada |
| Tolmar Pharmaceuticals, INC. | $195.73 | 2021-2022 | |
| Verity Pharmaceuticals INC. | $175.66 | 2022-2025 | Trelstar |
| Sanofi-Aventis U.S. LLC | $166.74 | 2022-2023 | |
| Endo Pharmaceuticals INC. | $163.71 | 2023 | Xiaflex |
| Teleflex LLC | $132.95 | 2021 | |
| Photocure INC | $117.89 | 2023 | Cysview |
| Antares Pharma, INC. | $103.02 | 2020-2021 | |
| Tempus Ai, INC | $87.65 | 2024-2025 | Xt Cdx |
| Immunitybio, INC. | $86.50 | 2024-2025 | |
| Caris Mpi, INC. | $71.83 | 2025 | Mi Cancer Seek |
| Palette Life Sciences, INC. | $59.71 | 2021-2022 | |
| Genzyme Corporation | $54.06 | 2022 | |
| Angiodynamics, INC. | $41.73 | 2022-2025 | Nanoknife |
| Rochester Medical Corporation | $41.70 | 2022 | |
| 180 Medical, INC. | $41.69 | 2019-2020 | |
| Clovis Oncology, INC. | $38.67 | 2020 | |
| Tolmar, INC. | $35.24 | 2023 | |
| Bard Access Systems, INC. | $24.14 | 2019 | |
| Boston Scientific Corporation | $21.61 | 2019 | |
| Civco Medical Instruments | $14.93 | 2024 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Dato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.